Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…Global access to Parkinson’s disease treatment
Objective: To examine the availability of PD treatment by country, and analyse differences by national income as defined by the World Bank (high income countries…Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS
Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…Directional steering in subthalamic deep brain stimulation for Parkinson’s disease: the Berlin experience
Objective: To review the use of directional current steering in a Berlin cohort implanted with segmented leads between 2016-2019. Background: The dorsolateral area of the subthalamic…Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies
Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW
Objective: To explore the current evidence and identify knowledge gaps, we conducted a scoping review about the hypoxia exposure effects on people with Parkinson’s disease…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat
Objective: To assess the effect of LY-404,039 on dyskinesia and parkinsonism in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD). Background: LY-404,039 is an…Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease
Objective: To evaluate the acceptability, feasibility, safety and effectiveness of a novel remotely delivered Parkinson’s care pathway. Background: Current care pathways for people with Parkinson’s…Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications
Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.
Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
- « Previous Page
- 1
- …
- 743
- 744
- 745
- 746
- 747
- …
- 1734
- Next Page »